Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 2020 Corporate Social Responsibility Report 癜颁奩眍買 Wu Yifang Chairman and CEO The year of 2020 marked as an extraordinary year. In ghting against coronavirus, full-scales epidemic prevention eorts has been carried out. Being one of active participants, many enterprises spared no eorts in ghting against the virus. Fosun Pharma, as the leading pharmaceutical and healthcare group in China, by comprehensively utilizing its industrial resources and global operational capabilities, respond timely to fulll its social responsibilities as a corporate citizen. Upon outbreak of the pandemic, Fosun Pharma joined hands with Fosun International in allocating medical supplies and resources for frontline treatment. Many doctors and nurses set up as Fosun medical units to the front line. Further, Fosun Pharma independently developed COVID-19 RT-PCR Detection Kit, manufactured and dispatched medical equipment such as ventilators, negative pressure ambulances and mobile CT for sucient supply. Vaccines are recognized as the ultimate means to ght against the pandemic. In search- ing for vaccines, Fosun Pharma decided to cooperate with BioNTech in developing mRNA vaccine, and proactively initiated the develop- ment of mRNA vaccine BNT162b2 in China. Innovation is the most important social responsibility for a pharmaceutical enterprise. In response to unsatised medical demands, Fosun Pharma aims to provide better, more convenient and more aordable products and services for more patients and customers through continuous innovation. We are glad to see that we have achieved outstanding innovation results in 2020. The innovative medicine Artesun® is recommended by WHO for the treatment of severe malaria, which has saved more than 30 million patients in Africa. Till the end of 2020, Fosun Pharma had successfully launched three biosimilars—Han Li Kang®, Han Qu You® and Han Da Yuan®; the new medicine Avatrombopag Maleate tablets (commodity name: Su Ke Xin®) has been approved by China NMPA for launch and included into the national medical insurance reimbursement list. Meanwhile, CAR-T cell therapy product Axicabtagene Ciloleucel injection product was granted priority review for the launch. Quality is the lifeline of a pharmaceutical enterprise. Adhering to the quality principle and concept of “Respect for Life, Focus on Quality, Commitment to Perfection, and Pursuit of Excellence”, we have established the production management and quality system in compli- ance with international standards. Since the launch of operation excellence (FOPEX) in 2017, we have continuously enhanced the internal operation eciency. We continued to implement FOPEX 2.0 system in 2020, achieving good results. In terms of environment, health and safety, we have continuously strengthened investment in environmental protection, and promoted the atmospheric pollution treatment following the concept of sustainable development, in order to reach goals in aspects of energy conservation, emission reduction and environmental protection. As our corporate culture manifested, Self-improvement, Teamwork, Development and Contribution to Society, we always remember to be grateful and give back to the society, and fulll our responsibility as a corporate citizen by supporting social welfare activities such as education, scientic research innovation and healthcare. In the future, adhering to the brand concept of "Innovation for Good Health", Fosun Pharma is committed to enabling every family to enjoy high-quality pharmaceutical products and healthcare services in a sustainable way, to bring good health to families worldwide. Wu Yifang Chairman and CEO of Fosun Pharma 2020 Corporate Social Responsibility Report 3 目 錄 About the Report 06-07 Responsible Employer 62-81 Attracting Talents Through Development Building Our Team Through A Common Cause Key Performance in 2020 08-09 Training Talents Through Their Works Evaluating Talents Through Their Performance • Staff trainings About Fosun Pharma 10-19 • Development of staff An innovation-driven international healthcare industrial • Protection of staff’s safety and health group with business strategically covering the phamaceutical and health industry Responsible Environmental Protection: 82-109 Build environmental-friendly community together • Company profile • Financial performance • EHS strategies and goals • Regulate corporate governance • Climate change risks and responses • Greenhouse gas emissions and energy management Responsible Management: In pursuit of the sustainability 20-29 of talents and products Responsible Community: Innovation for Good Health 110-121 • Fight with the pandemic and overcome the difficult period • Strategies for social responsibilities • Social welfare • Corporate governance • Practice of business ethnics Responsible Operation: Provision of assessable, aordable 30-55 Feedback Form 122 and reliable products and services • Quality first and outstanding operation • Enhance values for clients • Information security and protection of private information Indicator Index 123-136 Responsible Supply Chain: Win-win and sustainable 56-61 business partnership Assurance Statement 137-139 • Supplier management • Green supply chain 4 Innovation for Good Health 目 錄 About the Report 06-07 Responsible Employer 62-81 Attracting Talents Through Development Building Our Team Through A Common Cause Key Performance in 2020 08-09 Training Talents Through Their Works Evaluating Talents Through Their Performance • Staff trainings About Fosun Pharma 10-19 • Development of staff An innovation-driven international healthcare industrial • Protection of staff’s safety and health group with business strategically covering the phamaceutical and health industry Responsible Environmental Protection: 82-109 Build environmental-friendly community together • Company profile • Financial performance • EHS strategies and goals • Regulate corporate governance • Climate change risks and responses • Greenhouse gas emissions and energy management Responsible Management: In pursuit of the sustainability 20-29 of talents and products Responsible Community: Innovation for Good Health 110-121 • Fight with the pandemic and overcome the difficult period • Strategies for social responsibilities • Social welfare • Corporate governance • Practice of business ethnics Responsible Operation: Provision of assessable, aordable 30-55 Feedback Form 122 and reliable products and services • Quality first and outstanding operation • Enhance values for clients • Information security and protection of private information Indicator Index 123-136 Responsible Supply Chain: Win-win and sustainable 56-61 business partnership Assurance Statement 137-139 • Supplier management • Green supply chain 2020 Corporate Social Responsibility Report 5 幬苇香近羔 This is a corporate social responsibility (CSR) report published by Shanghai Fosun Pharmaceutical (Group) Co., Denitions: Ltd. for the thirteenth consecutive year. For the convenience of expression and reading, Fosun Pharma may be referred to, according to the context, as “the This report aims to truthfully present the CSR practice and achievements of the Group to our shareholders, Company”, “Fosun Pharma” or “the Listed Company” in the report; Fosun Pharma and its subsidiaries included in the employees, government agencies, customers and consumers, partners and other stakeholders. consolidated report may be referred to as “the Group”, or “Fosun Pharma Group” ; the wholly-owned subsidiaries of the Fosun Pharma are described as “member enterprises” ; Shanghai Fosun Pharmaceutical Industrial Development Basis of Report: Limited may be referred to as “Fosun Pharmaceutical Industrial Company” or “Industrial Company” . For more description of company names, please refer to the Definitions of enterprise name. This report is in line with the core plan of GRI sustainability reporting standards (GRI Standards) (GRI represents Global Reporting Initiative) and is also in compliance with requirements set out in the ESG Access to the Report: Reporting Guide in Appendix 27 to the Listing Rules issued by the Stock Exchange and is prepared with reference to the national standards on social responsibility (GB/T36000) and the Guidelines on Corporate The report is prepared and printed in simplified Chinese, traditional Chinese and English and is available in both Social Responsibility Reporting for Chinese Enterprises (CASS-CSR 4.0) published by the Corporate Social hardcopy and electronic versions. The latter may be downloaded from the website of Fosun Pharma Responsibility Research Center of School of Economics of Chinese Academy of Social Sciences. (https://www.fosunpharma.com/about/CSR.aspx). In case of any disparity between different versions, the version in simplified Chinese shall prevail. Reporting Period: Report Assurance: 1 January 2020 to 31 December 2020 An external institution has been commissioned by Fosun Pharma to perform third party verification of the Chinese Scope of Report : CSR report and issued an Assurance Statement. The Assurance Statement covers the head office of Fosun Pharma as well as the on-site assurance of pharmaceutical subsidiaries Fosun Long March and Yaneng Bio. The scope of enterprises disclosed in this report is consistent with that of the 2020 Annual Report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Data Description: Please visit the official website of Fosun Pharma (www.fosunpharma.com) for more information on how the Group implements the concepts and